Long term combination treatment with bevacizumab, pegylated liposomal doxorubicin and regional abdominal hyperthermia in platinum refractory ovarian cancer: A case report and review of the literature

Anticancer Research

Volumn 31, Issue 8, 2011, Pages 2675-2677

  Pietzner, Klaus ^a   Schmuck, Rosa Bianca ^a   Fotopoulou, Christina ^a   Gellermann, Johanna ^a   Ismaeel, Fakher ^a   Cho, Chie Hee ^b   Kalden, Michael ^c   Sehouli, Jalid ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c Private Practice   (Germany)

Author keywords

Bevacizumab; Doxorubicin; Hyperthermia; Ovarian cancer; Platinum refractory

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DOXORUBICIN; GEMCITABINE; MACROGOL; PACLITAXEL; TREOSULFAN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CASE REPORT; CLINICAL EVALUATION; COLON RESECTION; CYTOREDUCTIVE SURGERY; DIARRHEA; FATIGUE; FEMALE; HUMAN; HYPERTENSION; HYPERTHERMIC THERAPY; ILEORECTAL ANASTOMOSIS; LONG TERM CARE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PELVIS CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; WOUND HEALING IMPAIRMENT;

ABDOMEN; ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; OVARIAN NEOPLASMS;

EID: 79961179619     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Alberts DS: Treatment of refractory and recurrent ovarian cancer. Semin Oncol 26(1 Suppl 1): 8-14, 1999.
2. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME and Lacave AJ: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14): 3312-3322, 2001. (Pubitemid 32642183)
3. Han ES and Monk BJ: Bevacizumab in the treatment of ovarian cancer. Expert Rev Anticancer Ther 7(10): 1339-1345, 2007.
4. Burger RA, Sill MW, Monk BJ, Greer BE and Sorosky JI: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25(33): 5165-5171, 2007. (Pubitemid 350237599)
5. Cho CH, Wust P, Hildebrandt B, Issels RD, Sehouli J, Kerner T, Deja M, Budach V and Gellermann J: Regional hyperthermia of the abdomen in conjunction with chemotherapy for peritoneal carcinomatosis: evaluation of two annular-phased-array applicators. Int J Hyperthermia 24(5): 399-408, 2008.
6. Fotopoulou C, Hee Cho C, Kraetschell R, Gellermann J, Wust P, Lichtenegger W and Sehouli J: Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study. Int J Hyperthermia 26(2): 118-126, 2010.
7. Dewhirst MW, Vujaskovic Z, Jones E and Thrall D: Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia 21(8): 779-790, 2005. (Pubitemid 41818597)
8. Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R and Riess H: The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 43(1): 33-56, 2002.
9. Grenader T, Goldberg A and Gabizon A: Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up? Anticancer Drugs 21(9): 868-871, 2010.